GlassScriptPhysician profile
Andrew Paul Benoit
NPI 1184840902
$3,526.29
in general payments reported to CMS, 2019-2025
26 companies · $18.88 in 2025
The $18.88 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $750 · 2022: $938 · 2023: $1,094 · 2024: $725 · 2025: $18.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.02 | 2021-2025 | |
| Novo Nordisk INC | $690.65 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $363.25 | 2021-2024 | Farxiga |
| Pfizer INC. | $280.84 | 2021-2024 | |
| Abbott Laboratories | $240.64 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $195.91 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $189.12 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $166.04 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.36 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $67.79 | 2021-2022 | |
| Lundbeck LLC | $39.12 | 2023-2024 | Rexulti |
| Amgen INC. | $38.43 | 2023 | Repatha |
| Astellas Pharma US INC | $37.45 | 2022-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.38 | 2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $32.35 | 2023 | Livalo, Seglentis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $32.23 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.95 | 2024 | |
| Avanir Pharmaceuticals, INC. | $21.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.06 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $14.92 | 2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $13.97 | 2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $13.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.32 | 2021 | |
| Eisai INC. | $11.21 | 2021 | |
| Genentech USA, INC. | $6.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.